Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Nearly 50% of patients were initially prescribed LABA/inhaled corticosteroids. BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients ...

The Spanish COPD guidelines recommend treatment of the ... to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more severe cases, theophylline or roflumilast may ...

A total of 2,802 patients with COPD were randomised 1:1 to receive FF ... Patients who were taking a LAMA in addition to ICS/LABA therapy (triple therapy) who were randomised to the FF/VI group ...

Chronic obstructive pulmonary disease; ICS: Inhaled corticosteroids; LABA: Long-acting β 2-agonists; LAMA: Long-acting antimuscarinic antagonists; LTRA: Leukotriene receptor antagonists ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...